On Wednesday, Following U.S. Stocks were among the “Top Losers”: Endurance International Group, (NASDAQ:EIGI), Orexigen Therapeutics, (NASDAQ:OREX), Tyson Foods, (NYSE:TSN), Idera Pharmaceuticals, (NYSE:IDRA)
Endurance International Group, (NASDAQ:EIGI), with shares dwindled -5.63%, closed at $18.11.
Tyson Foods, (NYSE:TSN), with shares declined -5.61%, settled at $37.55.
Orexigen Therapeutics, (NASDAQ:OREX), with shares dipped -5.07%, and closed at $6.93.
Idera Pharmaceuticals, (NYSE:IDRA), dropped -4.71%, and closed at $4.45.
Latest NEWS regarding these Stocks are depicted underneath:
Endurance International Group Holdings, Inc. (NASDAQ:EIGI)
Endurance International Group Holdings, Inc. (EIGI), a leading provider of cloud-based platform solutions designed to assist small and medium-sized businesses succeed online, declared the completion of the formerly declared sale of shares of its ordinary stock by existing stockholders. In the offering, certain existing stockholders identified in the prospectus supplement regarding the offering sold 13,800,000 shares of ordinary stock, counting 1,800,000 shares sold upon the exercise in full of the underwriter’s option to purchase additional shares from the selling stockholders. Endurance will not receive any proceeds from the sale of shares of ordinary stock by the selling stockholders.
Credit Suisse Securities (USA) LLC acted as the sole underwriter for the offering.
Endurance International Group Holdings, Inc., together with its auxiliaries, provides cloud-based platform solutions for small-and medium-sized businesses worldwide.
Tyson Foods, Inc. (NYSE:TSN)
Tyson Foods, Inc. (TSN), executives will be presenters at the Consumer Analyst Group of Europe (CAGE) annual conference in London on Wednesday, March 18, at 8:15 a.m. GMT (4:15 a.m. EDT, 3:15 a.m. CDT). Dennis Leatherby, executive vice president and chief financial officer; and Andy Callahan, president, retail packaged brands; will be the speakers.
Tyson Foods, Inc. (TSN), with headquarters in Springdale, Arkansas, together with its auxiliaries, produces, distributes, and markets chicken, beef, pork, prepared foods, and related allied products worldwide.
Orexigen Therapeutics, Inc. (NASDAQ:OREX)
Formerly on February 25, Orexigen Therapeutics, Inc. (OREX), declared business and financial results for the fourth quarter and year ended December 31, 2014.
Financial results for the three months ended December 31, 2014:
For the three months ended December 31, 2014, Orexigen stated a net profit of $0.6 million, or $0.00 per share, as contrast to a net loss of $21.5 million, or $0.21 per share, for the fourth quarter of 2013.
Total operating expenses for the fourth quarter of 2014 were $20.6 million contrast to $21.8 million for the fourth quarter of 2013.
Financial results for the year ended December 31, 2014:
For the year ended December 31, 2014, Orexigen stated a net loss of $37.5 million, or $0.32 per share, as contrast to a net loss of $77.7 million, or $0.80 per share, for 2013. Total operating expenses for 2014 were $86.1 million contrast to $80.6 million for 2013. This overall rise in operating expenses primarily reflects an raise in raw materials, inventory, and manufacturing-related expenses and in stock based compensation expense. The overall raise was partially offset by a decrease in research and development expenses associated with the conduct of the Light Study, the Contrave cardiovascular outcomes trial. While Orexigen is responsible for manufacturing Contrave, Takeda will reimburse Orexigen for manufacturing related costs, counting finished goods.
As of December 31, 2014, Orexigen had $104.2 million in cash and cash equivalents and an additional $101.3 million in marketable securities, for a total of $205.5 million.
Orexigen Therapeutics, Inc., a biopharmaceutical corporation, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen developed Contrave® (naltrexone HCl and bupropion HCl extended release), which is approved in the United States and is being commercialized there by the corporation’s North American partner, Takeda Pharmaceuticals.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Formerly on February 19, Idera Pharmaceuticals, Inc. (IDRA), declared the closing of its formerly declared underwritten public offering of 23,000,000 shares of ordinary stock at an offering price of $3.75 per share. The shares of ordinary stock in the offering comprise 3,000,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the offering price. The gross proceeds to Idera from this offering total $86.25 million, before underwriting discounts and commissions and offering expenses. Goldman, Sachs & Co. and J.P. Morgan acted as joint bookrunning managers for the offering. Piper Jaffray & Co. acted as lead manager for the offering.
Idera Pharmaceuticals, Inc., a clinical stage biotechnology corporation, is engaged in the discovery and development of novel therapeutics that modulate immune responses through toll-like receptors (TLRs) in the United States. Idera’s proprietary technology involves using a Toll-like receptor (TLR) targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
